Skip to main content
Nectar Lifesciences Limited logo

Nectar Lifesciences Limited — Investor Relations & Filings

Ticker · NECLIFE ISIN · INE023H01027 LEI · 335800RY4LGC64KN9C05 BSE.NS Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country IN India
Listing BSE.NS NECLIFE

About Nectar Lifesciences Limited

https://www.neclife.com/

Nectar Lifesciences Limited is a pharmaceutical organization specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the cephalosporin segment, producing a wide range of oral and sterile products including Cefixime, Cefuroxime Axetil, and Ceftriaxone. Its operations encompass a fully integrated business model supported by large-scale manufacturing facilities that adhere to international regulatory standards such as USFDA and EUGMP. In addition to its core antibiotic portfolio, the company produces menthol and phytochemicals. Nectar Lifesciences serves a global clientele through contract manufacturing and development services, leveraging its research and development capabilities to provide high-quality therapeutic solutions across various international markets.

Recent filings

Filing Released Lang Actions
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Regulatory Filings Classification · 80% confidence The document is a formal notice to stock exchanges informing of a scheduled Board Meeting to consider and approve audited financial results and financial statements. It is not the actual financial report, a proxy or AGM notice, nor a management change announcement. This is a general regulatory announcement under listing obligations. Therefore, it falls under the fallback category Regulatory Filings (RNS).
2026-05-25 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the transfer of a business segment on a 'slump sale' basis. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations and provides an update on the extension of the expected completion date for the transaction. The content is an announcement about a capital transaction rather than a full financial report or detailed analysis. The document length is short (1941 characters), and it does not contain financial statements or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as business transfers or slump sales.
2026-04-28 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 95% confidence The document is a letter addressed to stock exchanges referencing Regulation 30 of SEBI LODR Regulations, which mandates disclosure of material events. The content focuses on updating the exchanges about litigation status and orders passed by regulatory or judicial authorities concerning the company. It includes details of a concluded tax litigation matter and clarifies a delay in disclosure. There are no financial statements, earnings data, or management discussion. The document is a regulatory disclosure about legal proceedings and compliance with listing obligations. It is not an audit report, annual report, or earnings release. The document fits best under Legal Proceedings Report (LTR) as it updates on significant lawsuits and regulatory actions involving the company.
2026-04-28 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2026-04-09 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a communication from Nectar Lifesciences Ltd. to stock exchanges regarding the launch of a shareholder outreach initiative called the 'Saksham Niveshak' campaign. The purpose is to help investors update KYC details and claim unpaid/unclaimed dividends to prevent transfer to the Investor Education and Protection Fund (IEPF) Authority. The document includes campaign details, instructions for shareholders, and contact information. It does not contain any financial statements, earnings data, management discussion, or regulatory certifications. It is an announcement of a shareholder initiative related to dividend claims and KYC updates, not a financial report or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-04-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, issued by the Registrar and Share Transfer Agent (Kfin Technologies Limited) to the company Nectar Lifesciences Ltd. It certifies the confirmation of securities dematerialization for the quarter ended March 31, 2026. The document is short (3102 characters), formal, and serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or any report content but is a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and confirmations.
2026-04-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.